X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (15) 15
oncology (14) 14
female (10) 10
male (9) 9
melanoma (8) 8
middle aged (8) 8
treatment outcome (8) 8
aged (7) 7
cancer (7) 7
cancer therapies (7) 7
hematology, oncology and palliative medicine (7) 7
metastasis (7) 7
tumors (7) 7
adult (6) 6
imatinib mesylate (6) 6
medicine (6) 6
mutation (6) 6
aged, 80 and over (5) 5
care and treatment (5) 5
chemotherapy (5) 5
dermatology (5) 5
history (5) 5
survival (5) 5
adolescent (4) 4
antineoplastic agents - therapeutic use (4) 4
clinical trials (4) 4
disease-free survival (4) 4
follow-up studies (4) 4
melanoma - drug therapy (4) 4
mutations (4) 4
neoplasm staging (4) 4
prognosis (4) 4
risk assessment (4) 4
sarcoma (4) 4
studies (4) 4
surgery (4) 4
young adult (4) 4
adjuvant imatinib (3) 3
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
combined modality therapy (3) 3
drug therapy (3) 3
gastrointestinal stromal tumors - drug therapy (3) 3
gastrointestinal stromal tumors - pathology (3) 3
hospitals (3) 3
immunotherapy (3) 3
kit (3) 3
medical colleges (3) 3
medicine, general & internal (3) 3
melanoma - genetics (3) 3
metastases (3) 3
patients (3) 3
pembrolizumab (3) 3
protein kinase inhibitors - therapeutic use (3) 3
skin (3) 3
skin neoplasms - pathology (3) 3
survival rate (3) 3
time factors (3) 3
abridged index medicus (2) 2
adjuvant chemotherapy (2) 2
alanine (2) 2
alanine transaminase (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
archaeology (2) 2
benzamides (2) 2
bone marrow (2) 2
child (2) 2
criteria (2) 2
diagnostics (2) 2
disease progression (2) 2
dna mutational analysis (2) 2
docetaxel (2) 2
dose imatinib (2) 2
double-blind method (2) 2
europe - epidemiology (2) 2
fda approval (2) 2
gastrointestinal neoplasms - drug therapy (2) 2
gastrointestinal neoplasms - genetics (2) 2
gastrointestinal neoplasms - pathology (2) 2
gastrointestinal stromal tumors - genetics (2) 2
gastrointestinal stromal tumors - mortality (2) 2
gist (2) 2
imidazoles - therapeutic use (2) 2
indoles - therapeutic use (2) 2
inhibition (2) 2
intention to treat analysis (2) 2
internal medicine (2) 2
ipilimumab (2) 2
kaplan-meier estimate (2) 2
land tenure (2) 2
melanoma - pathology (2) 2
melanoma - secondary (2) 2
mesylate (2) 2
metaanalysis (2) 2
motivation (2) 2
nanoparticles (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 550 - 560
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2019, Volume 20, Issue 8, pp. 1148 - 1159
SummaryBackgroundPathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving... 
Hematology, Oncology, and Palliative Medicine | INDUCED PATHOLOGICAL NECROSIS | NEOADJUVANT CHEMOTHERAPY | HIGH-GRADE | ONCOLOGY | EUROPEAN ORGANIZATION | HIGH-RISK | POSTOPERATIVE RADIOTHERAPY | EXTREMITY | RECURRENCE | RADIATION-THERAPY | Care and treatment | Sarcoma | Radiotherapy | Analysis | Hafnium | Index Medicus
Journal Article
Nowotwory, ISSN 0029-540X, 2014, Volume 64, Issue 4, pp. 343 - 345
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 265 - 274
Journal Article
Journal Article